Influence of the size of the cohorts in adaptive design for nonlinear mixed effect models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic.

Slides:



Advertisements
Similar presentations
Matthew M. Riggs, Ph.D. metrum research group LLC
Advertisements

The Innovative Medicines Initiative (IMI) The IMI Call and Evaluation Process Eva Lindgren.
Statistical Analysis for Two-stage Seamless Design with Different Study Endpoints Shein-Chung Chow, Duke U, Durham, NC, USA Qingshu Lu, U of Science and.
Response Optimization in Oncology In Vivo Studies: a Multiobjective Modeling Approach Maksim Pashkevich, PhD (Early Phase Oncology Statistics) Joint work.
A Proof-of-Concept Evaluation of Adverse Drug Reaction Surveillance in Electronic Health Records Zarif Jabbar-Lopez, MBBS, MPH FY2, East of England Deanery.
Design of Individualized Dosage Regimes using a Bayesian Approach J. M. Laínez, G. Blau, L. Mockus, S. Orçun & G. V. Rekalitis May 2011.
Approaches to incorporating pharmacoeconomic data into early drug discovery Kevin Sheehy Acting CEO Medicines New Zealand.
Mechanistic PBPK as an aid in identifying the size of covariate effects and design of POPPK studies: An example focusing on haematocrit as a determinant.
Verify or refute the use of Non Linear Mixed Effect Model for Interferon effect on HCV Hila David Shimrit Vashdi Project Advisors: Prof. Avidan Neumann.
Adaptive Designs for Clinical Trials
1 Design evaluation and optimization for models of hepatitis C viral dynamics Jeremie Guedj 1,2 Caroline Bazzoli 3 Avidan Neumann 2 France Mentré 3 1 Los.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April 22, 2003 Pediatric Population Pharmacokinetics Study.
EPAD update José Luis Molinuevo Worldwide-ADNI Update Meeting Friday, July 17, 2015 Washington, D.C.
1 Clinical PK Optimal design and QT-prolongation detection in oncology studies Sylvain Fouliard & Marylore Chenel Department of clinical PK, Institut de.
Dose-Finding with Two Agents in Phase I Oncology Trials Thall, Millikan, Mueller & Lee, Biometrics, 2003.
Adaptive designs as enabler for personalized medicine
MODEGAT Chalmers University of Technology Use of Latent Variables in the Parameter Estimation Process Jonas Sjöblom Energy and Environment Chalmers.
Modelling and Simulation Group, School of Pharmacy Pharmacokinetic design optimization in children and estimation of maturation parameters: example of.
Figure 2. The efficiency with the different optimizations compared to the standard design. 100 % effeciency indicates no improvement compared to the standard.
Results: In the presence of PD measurements, PK data provided little additional information. By a limited PD sampling the number of patients on target.
How much can we adapt? An EORTC perspective Saskia Litière EORTC - Biostatistician.
The Early Days of an Investigator in WIHS: Grants and Projects By Bani Tamraz, Pharm.D., Ph.D. Associate Clinical Professor School of Pharmacy.
Innovation Investment Package: the P2P Dimension - Article 185 Initiatives GPC Meeting Brussels, 4th September 2013 Sean O'Reagain Deputy Head of Unit.
Modeling of Longitudinal Tumor Size Data in Clinical Oncology Studies of Drugs in Combination N. Frances 1, L. Claret 2, F. Schaedeli Stark 3, R. Bruno.
EMEA London Pharmacokinetic- pharmacodynamic integration in veterinary drug development: an overview P.L. Toutain National Veterinary School ;Toulouse.
Center for Radiative Shock Hydrodynamics Fall 2011 Review Assessment of predictive capability Derek Bingham 1.
Use of Modelling for PKPD Studies in Infectious Diseases
Electromagnetic redesign of the HYPERcollar applicator: towards improved deep local head-and-neck hyperthermia *P. Togni, Z. Rijnen, W.C.M. Numan, R.F.
Traditional vs novel trial designing .
Rivaroxaban Has Predictable Pharmacokinetics (PK) and Pharmacodynamics (PD) When Given Once or Twice Daily for the Treatment of Acute, Proximal Deep Vein.
1 METHODS FOR DETERMINING SIMILARITY OF EXPOSURE-RESPONSE BETWEEN PEDIATRIC AND ADULT POPULATIONS Stella G. Machado, Ph.D. Quantitative Methods and Research.
Bayesian Model Robust and Model Discrimination Designs William Li Operations and Management Science Department University of Minnesota (joint work with.
Multivariate selective editing via mixture models: first applications to Italian structural business surveys Orietta Luzi, Guarnera U., Silvestri F., Buglielli.
1 Optimal design which are efficient for lack of fit tests Frank Miller, AstraZeneca, Södertälje, Sweden Joint work with Wolfgang Bischoff, Catholic University.
Designing Factorial Experiments with Binary Response Tel-Aviv University Faculty of Exact Sciences Department of Statistics and Operations Research Hovav.
Modelling and Simulation Lab, School of Pharmacy, University of Otago, New Zealand D-optimal Adaptive Bridging Studies in Pharmacokinetics Lee-Kien Foo.
"The challenge for Territorial Cohesion 2014 – 2020: delivering results for EU citizens" Veronica Gaffey Acting Director EUROPEAN COMMISSION, DG for Regional.
EHFG 7 October 2005 – Patient Safety & Research UK Presidency Workshop on Patient Safety, EHFG, Bad Hofgastein,7 September 2005 Kevin McCarthy, European.
Effect of Captopril first doses on Blood Pressure and Renal Function in Children with Congestive Cardiac Failure Dr Hussain Mulla, Co-Director, Centre.
1.Andersson, T, et al. Clin Pharmacokinet 2001;40: Hassan-Alin, M, et al. Eur J Clin Pharmacol 2000;56: Population Pharmacokinetic Modelling.
1. Objectives Novartis is developing a new triple fixed-dose combination product. As part of the clinical pharmacology program, pharmacokinetic (PK) drug-drug.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Improvement in Dose Selection Through Clinical PK/PD in Antimicrobial Drug Development: Perspective of an Industry PK/PD Scientist Gregory A. Winchell,
Impact of the inter-firm cooperation on company's performance: major changes during the economic crisis November 27, 2013 Oksana Kabakova.
Frank Bretz (Novartis) U Penn – April 13, 2016 Acknowledgment: Willi Maurer, Paul Gallo (Novartis) Adaptive Designs: The Swiss Army Knife Among Clinical.
Division of Pharmacokinetics and Drug Therapy Department of Pharmaceutical Biosciences Uppsala University Sweden Sequential versus Simultaneous.
| 1 Application of a Bayesian strategy for monitoring multiple outcomes in early oncology clinical trials Application of a Bayesian strategy for monitoring.
EUPATI Training Course Patient Experts in Medicines Research & Development The project is receiving support from the Innovative Medicines Initiative Joint.
European Patients’ Academy on Therapeutic Innovation – The project is receiving support from the.
HORIZON 2020 Launch Conference 16 January 2014, Kyiv, Ukraine.
The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement no ,
Pharmacometrics research group Department of Pharmaceutical Biosciences Uppsala University Approximations of the population Fisher information matrix-
European-Comparative Effectiveness Research on online Depression Treatment E-COMPARED is funded by the European Community’s Seventh Framework.
5. BRIDGING THE GAP between Pharmacometricians and Biostatisticians
On calibration of micro-crack model of thermally induced cracks through inverse analysis Dr Vladimir Buljak University of Belgrade, Faculty of Mechanical.
Multiple Model Dosage Design
Hanneke van der Lee, MD, PhD
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology
RAT SIMULATION RESULTS HUMAN SIMULATION RESULTS
Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Type and Amount of Information Provided Johan E. Wallin, Lena.
ACKNOWLEDGEMENTS The research leading to these results was conducted as part of the PROTECT consortium (Pharmacoepidemiological Research on Outcomes of.
High Performance Computing Center – HLRS
European Office Goswell House 134 Peascod Street Windsor, UK
EFPSI-BBS Meeting on M&S, Basel 13 September 2012
Penalized designs of multi-response experiments
UPTIME & SEMANTIC WEB STANDARDS
European Prevention Alzheimer’s Dementia
Detecting Treatment by Biomarker Interaction with Binary Endpoints
Assessing similarity of curves: An application in assessing similarity between pediatric and adult exposure-response curves July 31, 2019 Yodit Seifu,
Presentation transcript:

Influence of the size of the cohorts in adaptive design for nonlinear mixed effect models: an evaluation by simulation for a pharmacokinetic (PK) and pharmacodynamic (PD) model in oncology Giulia Lestini, Cyrielle Dumont, France Mentré IAME UMR 1137, INSERM, University Paris Diderot, Paris, France PODE September 11, 2014

Outline Context Objectives Methods Simulation Study Results Conlusion and Perspectives 2

Context: Optimal design in NLMEM Choosing a good design for a planned study is essential – Number of patients – Number of sampling times for each patient – Sampling times (allocation in time) Optimal design depends on prior information (model and parameters) D-optimality criterion – Local Designs – Robust designs Atkinson, Optimum Experimental Designs. (1995) Dodds et al., J Pharmacokinet Pharmacodyn. (2005) Pronzato and Walter, Math Biosci. (1988) 3

Context: Adaptive design AD: clinical trial designs that use accumulating information to decide how to modify predefined aspects of the study – Areas of interest: predicting clinical data; Phase 1 studies – ADs are useful to provide some flexibility but were rarely used for NLMEM Two-stage designs could be more efficient than fully adaptive design (not yet tested in NLMEM) Dumont et al. implemented two-stage AD in NLMEM AD questions: – How many adaptations? (e.g stages) – How many patients in each cohort? (i.e. cohorts size) 4 Foo et al., Pharm Res. (2012) Mentré et al., CPT Pharmacometrics Syst Pharmacol. (2013) Fedorov et al., Stat Med. (2012) Dumont et al., Commun Stat. (2014)

Objectives 1.To compare by simulation one and two-stage designs using a PKPD model in oncology 2.To study the influence of the size of each cohort in two-stage designs 3.To test extensions of two-stage adaptive design as three- and five-stage adaptive designs 5

Methods: Basic mixed effect model 6

Methods: Basic population design 7

Methods : Fisher Information Matrix (FIM) Mentré et al., Biometrika (1997) Bazzoli et al., Comput Methods Programs Biomed. (2010) Mentré et al., PAGE Abstr 3032 (2014) Dumont et al., Commun Stat. (2014) 8

Method: K-stage Adaptive Design 9 Design Optimisation Design Optimisation Estimation... Estimation Design Optimisation...

Concentration Simulation Study: PKPD Model CL/V kout ksyn Effect ka Gueorguieva et al., Comput Methods Programs Biomed. (2007) Gueorguieva et al., Br J Clin Pharmacol. (2014) Bueno et al., Eur J Cancer. (2008) 10

Simulation Study: Parameters PK Parameters PD Parameters

Simulation Study: Evaluated designs 12

Simulation Study: Clinical Trial Simulation 13

Results: 1-stage vs 2-stage balanced design Relative Estimation Error (REE) for PK parameters Ka and CL Ka RB RB CL 14

Results: 1-stage vs 2-stage balanced design Relative Estimation Error (REE) for PD parameters Kout and IC50 Kout RB RB IC50 15

Results: 1-stage vs 2-stage balanced design Relative Root Mean Squared Error (RRMSE) for PD parameters 16

Results: 1-stage vs 2-stage balanced design Relative Root Mean Squared Error (RRMSE) for PD parameters 17 * RRMSEs standardized to (best 1-stage design)

Results: Cohort size influence in 2-stage design Relative Root Mean Squared Error (RRMSE) for PD parameters 18

Results: Cohort size influence in 2-stage design Relative Root Mean Squared Error (RRMSE) for PD parameters 19 * RRMSEs standardized to (best 1-stage design)

Results: 2-stage vs 3- and 5-stage adaptive designs Relative Root Mean Squared Error (RRMSE) for PD parameters 20

Results: 2-stage vs 3- and 5-stage adaptive designs Relative Root Mean Squared Error (RRMSE) for PD parameters 21 * RRMSEs standardized to (best 1-stage design)

Results: 2-stage vs 3- and 5-stage adaptive designs Relative Root Mean Squared Error (RRMSE) for PD parameters 22 * RRMSEs standardized to (best 1-stage design)

Conclusions 23

Thank you for your attention ! 24 The research leading to these results has received support from the Innovative Medicines Initiative Joint Undertaking under grant agreement n° , resources of which are composed of financial contributions from the European Union's Seventh Framework Programme (FP7/ ) and EFPIA companies’ in kind contribution. The DDMoRe project is also financially supported by contributions from Academic and SME partners

Back up 25

Results: Cohort size influence in 2-stage design Relative Estimation Error (REE) for PK parameters Ka and CL Ka RB RB CL 26

Results: Cohort size influence in 2-stage design Relative Estimation Error (REE) for PD parameters Kout and IC50 Kout RB RB IC50 27

28 2 nd Stage3 rd Stage4 th Stage5 th Stage Designs Two-stage Three-stage Five-stage